ArticleFrontiers in neurology
Gut microbiota dynamics and its impact on the efficacy of ACTH therapy in infantile epileptic spasms syndrome.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Infantile epileptic spasms syndrome (IESS) is a severe early-life epileptic encephalopathy with diverse etiologies, yet its precise pathogenesis remains unclear. The gut-brain axis has emerged as a key modulator of neurodevelopment and seizure susceptibility, and although gut microbiota dysbiosis has been implicated in various epilepsy syndromes, its role in IESS, particularly in relation to treatment response, remains unexplored. This preliminary study therefore investigated gut microbiota composition in pediatric IESS and its potential as a biomarker of response to adrenocorticotropic hormone (ACTH) therapy. Methods: Eighteen patients with IESS were enrolled. Two age-matched control groups were established: a focal epilepsy (FE) group and a healthy (H) group. The 18 patients with IESS were subsequently categorized into two groups based on therapeutic response: ACTH-effective and ACTH-ineffective. Fecal samples were collected before and after ACTH treatment and subjected to 16S ribosomal DNA sequencing, followed by bioinformatics analyses. Results: Gut microbiota α-diversity was significantly lower in the IESS group than in the FE group, and β-diversity significantly differed among the IESS, FE, and H groups. Proteobacteria and Actinobacteria exhibited significantly higher relative abundances in the IESS group, while Ruminococcaceae was significantly lower than in the FE and H groups. The IESS group had significantly higher Veillonellaceae abundance but significantly lower Lachnospiraceae and Faecalibacterium abundances compared with the H group. Intestinal microbiota network structure was weaker in IESS than in the FE and H groups. Before ACTH treatment, the ACTH-ineffective subgroup exhibited significantly lower actinomycetes and bifidobacteria abundances, downregulated amino acid metabolism pathways, and weaker network aggregation than the effective subgroup. After treatment, the IESS group displayed enhanced network aggregation, significantly decreased Bacillus abundance, and downregulated retinol metabolism. Additionally, Corynebacteriales and Enterobacteriaceae were enriched before treatment, while Intestinibacter was enriched after treatment. Conclusion: Gut microbiota profiles in children with IESS suggested a potential association with response to ACTH therapy. These preliminary findings, while requiring validation in larger independent cohorts, highlight a potential role for the gut microbiota in the pathophysiology of IESS and underscore the need for further multi-omic investigations to elucidate underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.